Protein tyrosine phosphatase 1B(PTP1B) promotes melanoma cells progression through Src activation
- PMID: 34606417
- PMCID: PMC8806946
- DOI: 10.1080/21655979.2021.1988376
Protein tyrosine phosphatase 1B(PTP1B) promotes melanoma cells progression through Src activation
Abstract
Previous studies have demonstrated that protein tyrosine phosphatase 1B (PTP1B) can promote tumor progression in breast cancer, colon cancer and prostate cancer. Additionally, PTP1B also acts as a tumor suppressor in esophageal cancer and lymphoma. These findings suggest that PTP1B functions as a double-faceted molecule in tumors. However, the role of PTP1B in malignant melanoma (MM) is still unknown. PTP1B expression in normal and melanoma tissues was evaluated by GEO analysis and immunohistochemistry. The effects of PTP1B on cell migration and invasion were evaluated in melanoma cells with up - and downregulated PTP1B expression. In this study, we initially demonstrated that the expression of PTP1B in malignant melanoma tissue is significantly higher than its expression in benign nevus tissue and indicated poor survival of malignant melanoma patients. In vitro studies have demonstrated that inhibition of PTP1B suppresses and overexpression of PTP1B promotes migration and invasion of melanoma cells. Moreover, we found that PTP1B could interact with Src via coimmunoprecipitation and dephosphorylation of the Src at Tyr530 site. Collectively, our study revealed that PTP1B can promote melanoma cell metastasis by interacting with Src and provides a theoretical basis for future applications of PTP1B inhibitors in the treatment of malignant melanoma.
Keywords: Melanoma; metastasis; ptp1b; src.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures





Similar articles
-
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.Cancer Lett. 2015 Apr 10;359(2):218-25. doi: 10.1016/j.canlet.2015.01.020. Epub 2015 Jan 21. Cancer Lett. 2015. PMID: 25617799
-
Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.Cell Cycle. 2015;14(5):732-43. doi: 10.1080/15384101.2014.998047. Cell Cycle. 2015. PMID: 25590580 Free PMC article.
-
PTP1B contributes to calreticulin-induced metastatic phenotypes in esophageal squamous cell carcinoma.Mol Cancer Res. 2013 Sep;11(9):986-94. doi: 10.1158/1541-7786.MCR-12-0704. Epub 2013 Jun 27. Mol Cancer Res. 2013. PMID: 23814025
-
Inhibitors of Protein Tyrosine Phosphatase PTP1B With Anticancer Potential.Anticancer Res. 2019 Jul;39(7):3379-3384. doi: 10.21873/anticanres.13481. Anticancer Res. 2019. PMID: 31262859 Review.
-
Protein Tyrosine Phosphatase 1B (PTP1B): Insights into its New Implications in Tumorigenesis.Curr Cancer Drug Targets. 2022;22(3):181-194. doi: 10.2174/1568009622666220128113400. Curr Cancer Drug Targets. 2022. PMID: 35088671 Review.
Cited by
-
Translocator protein (18 kDa) regulates the microglial phenotype in Parkinson's disease through P47.Bioengineered. 2022 Apr;13(4):11061-11071. doi: 10.1080/21655979.2022.2068754. Bioengineered. 2022. PMID: 35475466 Free PMC article.
-
Predicting immunotherapy response in melanoma using a novel tumor immunological phenotype-related gene index.Front Immunol. 2024 Mar 20;15:1343425. doi: 10.3389/fimmu.2024.1343425. eCollection 2024. Front Immunol. 2024. PMID: 38571962 Free PMC article.
-
E2F transcription factor 1 is involved in the phenotypic modulation of esophageal squamous cell carcinoma cells via microRNA-375.Bioengineered. 2021 Dec;12(2):10047-10062. doi: 10.1080/21655979.2021.1996510. Bioengineered. 2021. PMID: 34699320 Free PMC article.
-
Critical roles of PTPN family members regulated by non-coding RNAs in tumorigenesis and immunotherapy.Front Oncol. 2022 Jul 26;12:972906. doi: 10.3389/fonc.2022.972906. eCollection 2022. Front Oncol. 2022. PMID: 35957898 Free PMC article. Review.
-
TRIP13/FLNA Complex Promotes Tumor Progression and Is Associated with Unfavorable Outcomes in Melanoma.J Oncol. 2022 Oct 11;2022:1419179. doi: 10.1155/2022/1419179. eCollection 2022. J Oncol. 2022. PMID: 36268276 Free PMC article.
References
-
- Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971–984. - PubMed
-
- Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. - PubMed
-
- Kudchadkar RR, Lowe MC, Khan MK, et al. Metastatic melanoma. CA Cancer J Clin. 2020;70(2):78–85. - PubMed
-
- Sun J, Carr MJ, Khushalani NI.. Principles of targeted therapy for melanoma. Surg Clin North Am. 2020;100(1):175–188. - PubMed
-
- Albittar AA, Alhalabi O, Glitza Oliva IC. Immunotherapy for melanoma. Adv Exp Med Biol. 2020;1244:51–68. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous